Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EPS (Weighted Average and Diluted) (2020 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at $144.57 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 366.54% year-over-year to $144.57; the TTM value through Dec 2025 reached -$3.32, up 97.84%, while the annual FY2025 figure was -$3.32, 98.38% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $144.57 in Q4 2025 per VRDN's latest filing, up from -$22.96 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $144.57 in Q4 2025 and bottomed at -$256.73 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$30.27, with a median of -$1.44 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 24966.2% in 2022, then soared 366.54% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.71 in 2021, then plummeted by 24966.2% to -$177.97 in 2022, then tumbled by 44.25% to -$256.73 in 2023, then soared by 78.87% to -$54.24 in 2024, then surged by 366.54% to $144.57 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $144.57 in Q4 2025, -$22.96 in Q3 2025, and -$124.06 in Q2 2025.